Neuraxpharm has launched Pezimax, the first oral solution of donepezil on the market, whose objective is to improve adherence to treatment in patients with mild to moderately severe dementia and Alzheimer’s and to facilitate its administration by caregivers.
Neuraxpharmlaboratory specialized in Central Nervous System (CNS)He has designed Pezimax for facilitate swallowingimprove adherence to treatment of patients with dementia and simplify administration by caregivers.
Alzheimer’s has devastating consequencesnot only for the patients but also for their environment, formed by the family, friends and caregivers. People affected by this pathology suffer problems with memory, behavior and other cognitive abilities, which progressively worsen. Over the years, the person’s ability to perform their daily activities decreases, while increases their dependence on the environment.
Dementia is becoming one of the great silent epidemics of the 21st century.
As you comment Javier MercadeCEO of , “the vulnerable situation in which people with dementia find themselves requires the search for solutions that meet their needs. At Neuraxpharm we maintain a firm commitment to research and the search for new treatments for the continuous improvement of patients suffering from diseases related to the Central Nervous System”.
“We are very aware that each new diagnosis changes the life of not only the patient, but also the entire family. In this sense, we have opted for a new solution that contributes to improve the daily life of the patient through a pharmaceutical form that facilitates adherence to treatment and the work of caregivers and family members”, says Javier Mercadé,
Alzheimer’s, the silent epidemic of the 21st century
The World Health Organization points out that Alzheimer’s and other dementias affect around 47 million people worldwide. Each year around 9.9 million new cases are diagnosed, which is equivalent to a new case diagnosed every three seconds. In Spain, the third country in the world with the highest prevalence of dementia, it is estimated that this degenerative disease affects more than 800,000 people.
As indicated by Neuraxpharm, the current context of increased life expectancy and progressive aging of the population has caused a very significant increase in the number of people with cognitive impairment and dementia that has generated an important socio-sanitary challenge. According to estimates, the number of people with dementia will increase considerably in the next 30 years, affecting approximately the 4% of the population in 2050.
The prevalence of this neurodegenerative disease in the Spanish population presents a . In this sense, in an increasingly aging population such as Spain, dementia is becoming one of the great silent epidemics of the 21st centuryin the shadow of other diseases with a symptomatology or a more obvious death rate.